论文部分内容阅读
目的观察艾塞那肽对二甲双胍及预混胰岛素治疗未能有效控制血糖的2型糖尿病患者的疗效。方法 90例入选的2型糖尿病患者随机分为二甲双胍组、预混胰岛素组、二甲双胍联合预混胰岛素组,给予口服最大耐受剂量二甲双胍及胰岛素治疗至少2个月,在此基础上加用艾塞那肽注射液,观察3个月测量糖化血红蛋白(HbAlc)、空腹血糖(FBG)、餐后2h血糖(PBG)、BMI变化情况。结果三组患者在原方案基础上加用艾塞那肽注射液治疗3月后HbAlc、FPG和PPG、BMI均较前降低(P<0.05)。结论使用艾塞那肽可改善T2DM患者的血糖和胰岛β细胞功能,并对降低体重有很好疗效。
Objective To observe the effect of exenatide on metformin and premixed insulin in patients with type 2 diabetes who failed to effectively control blood glucose. Methods 90 patients with type 2 diabetes mellitus were randomly divided into metformin group, premixed insulin group, metformin combined with premixed insulin group, given oral maximum tolerated dose of metformin and insulin therapy for at least 2 months, on the basis of the use of Essential The peptide injection was used to measure the changes of HbAlc, fasting blood glucose (FBG), postprandial 2h blood glucose (PBG) and BMI in 3 months. Results In the three groups, HbA1c, FPG, PPG and BMI were lower than those before (P <0.05) after exenatide injection for 3 months. Conclusion Exenatide can improve blood glucose and pancreatic β-cell function in patients with T2DM and has a good effect on reducing body weight.